| A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma? C Chung Blood and Lymphatic Cancer: Targets and Therapy, 99-106, 2022 | 2 | 2022 |
| Acute Myeloid Leukemia: From Molecular Pathogenesis to Oral Targeted Therapies C Chung US Pharmacist 44 (5(Specialty&Oncology suppl)), 4-8, 2019 | | 2019 |
| An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly (adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis C Chung, R Lee Journal of Oncology Pharmacy Practice 23 (6), 454-469, 2017 | 13 | 2017 |
| Current targeted therapies in lymphomas C Chung American Journal of Health-System Pharmacy 76 (22), 1825-1834, 2019 | 26 | 2019 |
| Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care C Chung American Journal of Health-System Pharmacy 80 (22), 1624-1636, 2023 | | 2023 |
| Development and implementation of an interdisciplinary oncology program in a community hospital C Chung, A Collins, N Cui American Journal of Health-System Pharmacy 68 (18), 1740-1747, 2011 | 44 | 2011 |
| Driving toward precision medicine for acute leukemias: are we there yet? C Chung, H Ma Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (9 …, 2017 | 18 | 2017 |
| Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level C Chung Journal of Oncology Pharmacy Practice 26 (4), 943-966, 2020 | 6 | 2020 |
| Focus on anemia in managing lower-risk myelodysplastic syndromes C Chung US Pharmacist 46 (19), 39-44, 2021 | | 2021 |
| From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer C Chung American Journal of Health-System Pharmacy 77 (24), 2064-2073, 2020 | 18 | 2020 |
| Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia C Chung, R Lee Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34 (12 …, 2014 | 20 | 2014 |
| Implementation of an integrated computerized prescriber order-entry system for chemotherapy in a multisite safety-net health system C Chung, S Patel, R Lee, L Fu, S Reilly, T Ho, J Lionetti, MD George, ... The Bulletin of the American Society of Hospital Pharmacists 75 (6), 398-406, 2018 | 44 | 2018 |
| Instilling value, quality, and safety through hematology and oncology stewardship C Chung, S Kim, J Bubalo American Journal of Health-System Pharmacy 76 (9), 617-621, 2019 | 2 | 2019 |
| Management of neuroendocrine tumors C Chung American Journal of Health-System Pharmacy 73 (21), 1729-1744, 2016 | 16 | 2016 |
| Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer C Chung American Journal of Health-System Pharmacy 79 (10), 717-718, 2022 | | 2022 |
| Neoadjuvant chemotherapeutic and targeted therapies for early-stage, high-risk breast cancer C Chung, R Lee Eur Oncol Haematol 10, 28-34, 2014 | 1 | 2014 |
| New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab C Chung Annals of Pharmacotherapy, 2020 | 6 | 2020 |
| Older adults may not consider life expectancy an important factor in cancer screening C Chung CA: A Cancer Journal for Clinicians 68 (1), 3-4, 2018 | 2 | 2018 |
| Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia C Chung American journal of health-system pharmacy 71 (4), 279-288, 2014 | 12 | 2014 |
| On the Forefront of Hematology and Oncology: A Clinical Pharmacist's Perspective CT Chung Cambridge Scholars Publishing, 2023 | | 2023 |
